Pawel Rajwa
@dr_rajwa
Followers
780
Following
4K
Media
21
Statuses
550
MD PhD FEBU I Member @EAU_YAUProstate I Editorial Board @WJUrol @CEJUrol @EAU_Uroonco I Board EUSP I Gen. Secretary for 🇵🇱 @PTUweb Annual Meetings
Polska
Joined December 2018
RT @DrYukselUrun: TAR-200 for BCG-unresponsive high-risk NMIBC. 🟡CR: 82%, DOR: 26 months (TAR-200 alone).🟡Best risk-benefit: TAR-200 monoth….
0
21
0
RT @DrFelixGuerrero: Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer ht….
jnj.com
New Drug Application supported by results from the Phase 2b SunRISe-1 study
0
7
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
620
2K
9K
RT @n_roessler: Early salvage RT matches adjuvant RT outcomes while reducing overtreatment in prostate cancer recurrence. Add PSMA-PET + s….
0
1
0
RT @COMPASSurology: Thank you for the honourable mention @declangmurphy, @NikitaB0709 & Mr Eoin Dinneen in the latest @EUplatinum podcast!….
0
6
0
RT @DrYukselUrun: 🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should in….
0
32
0
RT @DrYukselUrun: PEACE-3: Enzalutamide + Radium-223 improved rPFS (19.4 vs 16.4 mo) and OS (42.3 vs 35.0 mo) in mCRPC with bone mets. ⚠️Fr….
0
33
0
RT @Uroweb: In this week's 🎧 episode of #EAUPodcasts, Dr. Marcin Miszczyk and Prof. Wolfgang Fendler discussed the role of PSMA-PET imaging….
0
4
0
RT @Adam_Weiner535: 🚨Not all #prostatecancer BCRs are created equally!!🚨. 👉Many interesting takeaways in this Swedish population-based st….
0
24
0
RT @MRoupret: So proud of my team !!! 😎@EurUrolOncol we have a rise of one point of our impact factor over the last year. Congrats for the….
0
18
0
RT @Uroweb: 🎧 In today's episode of #EAUPodcasts, Assoc. Prof. Pawel Rajwa (PL) speaks with Prof. Peter Carroll (US) about the shifting lan….
0
3
0
RT @VickersBiostats: Have presented “Replace Gleason score with quantification of pattern 4 (after suitable research)” to > 30 different pr….
0
5
0
RT @bavilima: #ASCO25 #ProstateCancer. AMPLITUDE Trial 👉 PARPi in HRR+ mHSPC.▶️NIRA+AAP vs AAP.▶️ Better rPFS (HR 0.63; p=0.0001), particul….
0
6
0
RT @tompowles1: The positive CREST study (BCG + Sasanlimab) in NMIBC was published today (Neal Shore et al). #ASCO25
0
40
0
A key study from our team explores the role of ARPI monotherapy in prostate cancer. Findings suggest:. Toxicity is comparable to ARPI+ADT combination and ADT. Each regimen shows distinct AE & QoL profiles. ARPI may offer greater oncologic activity than ADT.
A new systematic review & meta-analysis explores the role of androgen receptor pathway inhibitor (ARPI) monotherapy across prostate cancer stages. •⚖️ Similar overall safety to ADT or ARPI+ADT combo.•❤️🔥 Fewer hot flushes.•⚠️ More breast-related side effects (pain &
0
7
29
RT @JGomezRivas: A new systematic review & meta-analysis explores the role of androgen receptor pathway inhibitor (ARPI) monotherapy across….
0
25
0
RT @DrShariat: PSA decline = survival signal in advanced #ProstateCancer.In a meta-analysis of 14 studies (n=8883), PSA response to ADT+ARP….
pubmed.ncbi.nlm.nih.gov
The PSA response following ADT + ARPI therapy is significantly associated with OS across all metastatic and castration-resistant PC states and could serve as a clinically useful early signal of...
0
7
0
RT @EurUrolFocus: What is the role of #PSA response in androgen receptor pathway inhibitors (#ARPI)?. @DrShariat @….
0
11
0
RT @EAU_Uroonco: 📹 In this expert video discussion, UROONCO PCa Assoc. Prof. @dr_rajwa is joined by Prof. @GertMeerleer & Dr. @roodvdb to t….
prostate.uroonco.uroweb.org
Our assoc. prof. Rajwa discussed the treatment of biochemical recurrence in PCa with experts Prof. De Meerleer & Dr. Van den Bergh.
0
2
0